Skip to main content

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

Withdrawn · Phase 3 · NCT06390722

Conditions: Atopic Dermatitis, Sleep Disturbance

At a glance

Research payments reported, 2025
$8,845
U.S. investigators named
2
Sites paid
2

About the trial

Sponsor
AbbVie
Tested
Upadacitinib (drug), Placebo for Upadacitinib (drug)
Dates
Started 2024-05-23; completion 2026-07-08
Results posted
Not yet

Many people with atopic dermatitis (AD) experience sleep disturbances. Greater sleep disturbances are associated with greater burden including increased sick days and impaired cognition. Patient focused research has found that sleep was one of the 3 most problematic symptoms for people with AD and their families. Upadacitinib demonstrated clinically meaningful sleep improvement based on patient-reported outcome measures such as the Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain score in Phase 3 registrational trials, but objective data on upadacitinib's effect on elements of sleep disturbance such as Wake After Sleep Onset, or Sleep Efficiency, have not been collected. Upadacitini…

From ClinicalTrials.gov, last updated 2024-09-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $8,845 in research payments for this study in 2025 (2 payments).

Products named: Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Wellness Clinical Research LLC $6,345
  • Great Lakes Research Group Inc $2,500

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.